Acasti Pharma’s (Acasti Pharma Stock Quote, Chart TSXV:ACST) third quarter results are in, but they’re of little consequence at the moment, says … [Read more...] about Acasti Pharma has tonnes of upside, Mackie Research says
Content brought to you by:
The Cantech Letter Life Sciences section is brought to you by Relay Medical Corp. (CSNX:RELA). Relay is in the business of commercializing innovative technologies, protected by issued and pending patents, in the medical diagnostics and research field with an emphasis on In Vitro Diagnostics (IVD) and Point of Care Testing (POCT). Click on the logo for more info...
With its cannabis oil extraction in the process of getting off the ground Neptune Wellness Solutions (Neptune Wellness Solutions Stock Quote, Chart … [Read more...] about Neptune Wellness Solutions has a 71 per cent upside, Echelon Wealth says
A realignment of its drug development efforts has Paradigm Capital analyst Rahul Sarugaser remaining bullish on Tetra Bio-Pharma (Tetra Bio-Pharma … [Read more...] about Tetra Bio-Pharma shakeup gets thumbs up at Paradigm Capital
Life sciences investors looking for a penny stock with potential should be considering Kalytera Therapeutics (Kalytera Therapeutics Stock Quote, Chart … [Read more...] about Kalytera Therapeutics has a huge upside, Echelon says
News that Swiss multinational Roche Holding AG is shutting down two late-stage studies of its Alzheimer drug has been greeted as the latest in a … [Read more...] about Could Roche’s Alzheimer’s drug failure be Promis Neurosciences gain?
In a research update on Monday, Echelon Wealth Partners analyst Douglas Loe reiterated his “Speculative Buy” rating and $1.40 target price for … [Read more...] about Buy Antibe Therapeutics for a 318 per cent return, says Echelon Wealth
Clinical-stage biopharmaceutical company Zymeworks (Zymeworks Stock Quote, Chart TSX, NYSE:ZYME) reported on Monday that Eli Lilly, one of ZYME’s … [Read more...] about Zymeworks stock is a buy, Paradigm Capital says
Paradigm Capital analyst Rahul Sarugaser is calling 2019 a breakout year for medical device company Profound Medical (Profound Medical Stock Quote, … [Read more...] about Profound Medical still has a huge upside, says Paradigm Capital
Specialty pharma company Acerus Pharmaceuticals (Acerus Pharmaceuticals Stock Quote, Chart TSX:ASP) has reported an anticipated shortage in its … [Read more...] about There’s still tons of upside in Acerus Pharmaceuticals, Mackie Research says
Commercial-stage specialty pharma company Knight Therapeutics (Knight Therapeutics Stock Quote, Chart TSX:GUD) has entered into a licensing agreement … [Read more...] about New deal for Knight Therapeutics doesn’t move the needle, says Mackie Research